197 related articles for article (PubMed ID: 34118178)
1. Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products.
Zhang S; Jin S; Griffin C; Feng Z; Lin J; Baratta M; Brake R; Venkatakrishnan K; Gupta N
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1028-1043. PubMed ID: 34118178
[TBL] [Abstract][Full Text] [Related]
2. Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers.
Zhang S; Jin S; Griffin C; Feng Z; Lin J; Venkatakrishnan K; Gupta N
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1044-1053. PubMed ID: 34145979
[TBL] [Abstract][Full Text] [Related]
3. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects.
Namour F; Vanhoutte FP; Beetens J; Blockhuys S; De Weer M; Wigerinck P
Drugs R D; 2012 Sep; 12(3):141-63. PubMed ID: 22950522
[TBL] [Abstract][Full Text] [Related]
5. Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with
Riely GJ; Neal JW; Camidge DR; Spira AI; Piotrowska Z; Costa DB; Tsao AS; Patel JD; Gadgeel SM; Bazhenova L; Zhu VW; West HL; Mekhail T; Gentzler RD; Nguyen D; Vincent S; Zhang S; Lin J; Bunn V; Jin S; Li S; Jänne PA
Cancer Discov; 2021 Jul; 11(7):1688-1699. PubMed ID: 33632775
[TBL] [Abstract][Full Text] [Related]
6. The Effect of a High-Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M; Gupta N; Hanley MJ; Venkatakrishnan K; Sonnichsen D; Kerstein D; Dorer DJ; Narasimhan N
Clin Pharmacol Drug Dev; 2019 Aug; 8(6):734-741. PubMed ID: 30570839
[TBL] [Abstract][Full Text] [Related]
7. Effects of a High-fat Meal on the Pharmacokinetics of the VEGFR Inhibitor Fruquintinib: A Randomized Phase I Study in Healthy Subjects.
Qian H; Fan S; Li K; Sai Y; Su W; Chen Q; Liu Y; Li T; Wang W; Jia J; Yu C; Liu Y
Clin Ther; 2019 Aug; 41(8):1537-1544. PubMed ID: 31272709
[TBL] [Abstract][Full Text] [Related]
8. First-in-human, phase I single-ascending-dose study of the safety, pharmacokinetics, and relative bioavailability of selatinib, a dual EGFR-ErbB2 inhibitor in healthy subjects.
Wang MN; Kuang Y; Gong LY; Hua Y; Pei Q; Guo CX; Cao Y; Huang J; Yang GP
Invest New Drugs; 2020 Dec; 38(6):1826-1835. PubMed ID: 32535812
[TBL] [Abstract][Full Text] [Related]
9. Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects.
Lau YY; Gu W; Lin T; Song D; Yu R; Scott JW
J Clin Pharmacol; 2016 May; 56(5):559-66. PubMed ID: 26272586
[TBL] [Abstract][Full Text] [Related]
10. Development and Validation of a LC-MS/MS Method for Quantification of Mobocertinib (TAK-788) in Plasma and its Application to Pharmacokinetic Study in Rats.
Li B; Wang J; Dou X; Zhang X; Xue X; Xu Q; Ran W; Xiong S
Comb Chem High Throughput Screen; 2021; 24(9):1410-1416. PubMed ID: 33155888
[TBL] [Abstract][Full Text] [Related]
11. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
Godfrey AR; Digiacinto J; Davis MW
Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
[TBL] [Abstract][Full Text] [Related]
12. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects.
Taylor L; Gidal B; Blakey G; Tayo B; Morrison G
CNS Drugs; 2018 Nov; 32(11):1053-1067. PubMed ID: 30374683
[TBL] [Abstract][Full Text] [Related]
13. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [
Hanley MJ; Zhang S; Griffin R; Zhu SX; Fram RJ; Lin J; Venkatakrishnan K; Gupta N
Invest New Drugs; 2024 May; ():. PubMed ID: 38789848
[TBL] [Abstract][Full Text] [Related]
16. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
17. First-in-Human Study for a Selective Rearranged During Transfection Tyrosine Kinase Inhibitor, GSK3352589, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.
Reedy BA; O'Connor-Semmes R; Hacquoil K; Gorycki P; Verticelli A; Molga A
Clin Pharmacol Drug Dev; 2021 Apr; 10(4):334-345. PubMed ID: 33606922
[TBL] [Abstract][Full Text] [Related]
18. A Phase I, Randomized, Crossover, Open-label Study of the Pharmacokinetics of Solriamfetol (JZP-110) in Healthy Adult Subjects With and Without Food.
Zomorodi K; Kankam M; Lu Y
Clin Ther; 2019 Feb; 41(2):196-204. PubMed ID: 30598342
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of crizotinib absolute bioavailability, the bioequivalence of three oral formulations, and the effect of food on crizotinib pharmacokinetics in healthy subjects.
Xu H; O'Gorman M; Boutros T; Brega N; Kantaridis C; Tan W; Bello A
J Clin Pharmacol; 2015 Jan; 55(1):104-13. PubMed ID: 24990113
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
Tomkinson H; McBride E; Martin P; Lisbon E; Dymond AW; Cantarini M; So K; Holt D
Clin Ther; 2017 Nov; 39(11):2260-2275.e1. PubMed ID: 28985960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]